Intuitive Surgical delivered another strong quarterly performance, reflecting sustained adoption of robotic-assisted surgical technologies across hospitals and healthcare systems worldwide. The company’s second-quarter results demonstrated continued expansion in procedure volumes, system installations, and profitability, reinforcing investor confidence in the long-term growth trajectory of minimally invasive surgery.

As healthcare providers continue investing in advanced surgical platforms to improve patient outcomes and operational efficiency, Intuitive Surgical remains one of the industry’s dominant technology providers. The latest results underscore the resilience of healthcare capital spending despite ongoing macroeconomic uncertainty.

Revenue and Earnings Reflect Broad-Based Operational Strength

Intuitive Surgical generated $2.89 billion in second-quarter revenue, representing a 19% increase compared with the same period in 2025. The company reported GAAP net income of $818 million, or $2.29 per diluted share, while non-GAAP net income reached $1.00 billion, or $2.80 per diluted share.

Financial performance benefited from increased procedure volumes, continued demand for robotic surgical systems, and growth in recurring revenue generated through instruments, accessories, and service contracts. A one-time benefit related to tariff refunds also contributed approximately $28 million, or $0.08 per diluted share, to quarterly earnings.

The combination of expanding revenue and improving profitability illustrates the scalability of Intuitive Surgical’s business model, where a growing installed base supports recurring sales over time.

Procedure Growth and System Placements Continue to Expand

Operational metrics remained particularly strong during the quarter. Combined da Vinci and Ion worldwide procedures increased approximately 16% compared with the previous year. Da Vinci procedures grew approximately 15%, while Ion procedures expanded approximately 36%, reflecting growing physician adoption of robotic-assisted technologies.

The company placed 468 da Vinci surgical systems during the quarter, including 246 next-generation da Vinci 5 systems, compared with 395 total system placements during the same quarter last year. Additionally, Intuitive installed 55 Ion endoluminal systems, maintaining steady momentum in its lung biopsy platform.

These figures demonstrate continued capital investment by healthcare providers despite higher financing costs, suggesting hospitals remain committed to expanding robotic-assisted surgical capabilities.

Installed Base Supports Long-Term Competitive Position

Intuitive Surgical ended the quarter with an installed base of 11,710 da Vinci systems, representing a 12% increase from one year earlier. The installed base of Ion systems grew even faster, increasing 21% to 1,096 systems.

A larger installed base strengthens the company’s recurring revenue profile because each surgical system generates ongoing demand for disposable instruments, accessories, software upgrades, and maintenance services. This recurring revenue model provides greater earnings visibility than companies relying solely on equipment sales.

The company also demonstrated continued capital discipline by repurchasing approximately 0.9 million shares for $380 million during the quarter, reflecting confidence in its long-term financial position while returning capital to shareholders.

Looking ahead, investors will continue monitoring procedure growth, adoption of the da Vinci 5 platform, expansion of the Ion system, and hospital capital spending trends. Continued innovation in robotic-assisted surgery, combined with an expanding installed base and recurring revenue streams, positions Intuitive Surgical to benefit from the long-term global shift toward minimally invasive surgical procedures while maintaining leadership in one of healthcare technology’s fastest-growing segments.